Across 63 European CTIS-authorized Phase II/III head and neck cancer trials, 26 trials used CRO or vendor support, equal to 41.3% of the cohort. The most active named support organizations were Almac, IQVIA, and Medidata, each appearing in 6 trials; among full-service CRO families, IQVIA led with 6 trials, followed by ICON, Parexel, and PPD/Thermo Fisher with 5 trials each. CRO need was most concentrated in operationally complex trials: 11 of 13 trials with 7 or more countries used CRO support, and 14 of 19 trials with 21 or more sites used CRO support.
CTIS sponsor records identified CRO/vendor support in 26 of 63 trials. Almac, IQVIA, and Medidata each supported 6 trials, equal to 23.1% of CRO-supported trials and 9.5% of all trials. ICON, Parexel, and PPD/Thermo Fisher each appeared in 5 trials.
The CRO field is split between full-service trial operators and specialist platform/supply vendors. For commercial targeting, IQVIA, ICON, Parexel, PPD/Thermo Fisher, Medpace, and Syneos represent the clearest full-service CRO opportunity set, while Almac and Medidata signal high demand for IMP supply and trial data infrastructure.
CRO use rose sharply with country and site burden. Only 3 of 31 single-country trials used CRO support, while 11 of 13 trials with 7 or more countries used CRO support. Site count showed the same pattern: 14 of 19 trials with 21 or more sites used CRO support.
| Capacity signal | Highest CRO-use band | CRO use | Rate |
|---|---|---|---|
| Countries | 7+ countries | 11 / 13 | 84.6% |
| Countries | 4–6 countries | 6 / 7 | 85.7% |
| Sites | 21+ sites | 14 / 19 | 73.7% |
| Disease breadth | 4+ diseases / basket scope | 12 / 18 | 66.7% |
| Participants | 151–300 participants | 7 / 13 | 53.8% |
Country count and site count are the strongest operational triggers for CRO involvement. The practical threshold is around 4 or more countries, where CRO use jumps to 17 of 20 trials, and 21 or more sites, where CRO use reaches 14 of 19 trials. Participant count alone is less predictive than CTIS country footprint and site-management burden.
CRO support was most common in multi-cancer or solid-tumour basket trials that included HNSCC, with 14 of 21 trials using CRO support. Recurrent/metastatic HNSCC also showed above-average outsourcing, with 5 of 9 trials using CRO support.
| Indication segment | Trials | CRO trials | Rate |
|---|---|---|---|
| Multi-cancer / solid-tumour basket | 21 | 14 | 66.7% |
| Recurrent/metastatic HNSCC | 9 | 5 | 55.6% |
| Head & neck supportive-care / oral mucositis | 2 | 1 | 50.0% |
| General HNSCC / head & neck cancer | 21 | 5 | 23.8% |
| Locally advanced HNSCC | 5 | 1 | 20.0% |
| Oropharyngeal SCC | 4 | 0 | 0.0% |
CRO demand is highest where HNSCC is embedded in broader oncology platform or basket studies, not only in pure HNSCC trials. Recurrent/metastatic HNSCC is the strongest pure head-and-neck segment for outsourced trial operations, reflecting larger international footprints and more commercial sponsor involvement.
The cohort covered 22 European countries, 232 country-trial participations, 1,321 trial-level sites, and 9,972 planned participants. France carried the largest CTIS Part II and site footprint, appearing in 36 trials with 361 country-level sites and 3,251 country-level participants.
| Country | Trials | Sites | Participants | CRO-linked trials | Median CTIS processing |
|---|---|---|---|---|---|
| France | 36 | 361 | 3,251 | 21 / 36 | 221 days |
| Spain | 31 | 235 | 1,105 | 22 / 31 | 284.5 days |
| Germany | 24 | 168 | 957 | 17 / 24 | 231 days |
| Italy | 22 | 165 | 659 | 15 / 22 | 238 days |
| Belgium | 19 | 83 | 697 | 14 / 19 | 237.5 days |
| Poland | 16 | 68 | 296 | 12 / 16 | 351 days |
EU submission workload is concentrated in France, Spain, Germany, Italy, Belgium, and Poland. These countries combine high site density with repeated CTIS Part II authorization activity, making them the highest-value geographies for CROs offering country start-up, site contracting, local regulatory operations, and submission management.
Thirty-eight of 63 trials listed at least one third-party support organization. Among those outsourced trials, central lab, biomarker, and PK testing was the most common function, appearing in 28 of 38 outsourced trials, followed by IMP supply/packaging/distribution in 21 of 38 trials.
The highest outsourcing demand is not only full trial management. HNSCC Phase II/III trials frequently outsource specialist execution layers: biomarker and PK testing, IMP logistics, data systems, imaging, and patient support. CTIS/EU submission support appears in 6 outsourced trials, indicating a narrower but commercially relevant regulatory-services segment.
The same CTIS dataset can answer several adjacent business-development questions beyond the CRO ranking. The strongest signals are sponsor type, adaptive design, and recurring site concentration.
The strongest adjacent targeting logic is to prioritize pharma-sponsored, adaptive, multi-country HNSCC trials with recurring participation from France, Spain, Germany, Italy, Belgium, and Poland. For CTIS/EU submission services, the best targets are sponsors running 4+ country trials or basket protocols that require repeated national Part II submissions and site-level authorization tracking.
CRO/vendor support means a third party listed in CTIS sponsor data under CRO-present records or operational third-party support. CTIS means the Clinical Trials Information System used for EU clinical-trial authorization. Part II refers to country-level assessment and authorization activity. HNSCC means head and neck squamous cell carcinoma. IMP means investigational medicinal product. IRT means interactive response technology. eCOA means electronic clinical outcome assessment. PK means pharmacokinetics.